Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)

@article{Tomova2009ConcomitantDP,
  title={Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperative Oncology Group (CECOG)},
  author={Antoaneta Tomova and Rupert Bartsch and Thomas Brodowicz and Valentina Tzekova and Constanta Timcheva and Christoph Wiltschke and Dany Abi Gerges and Jan Pawlega and Stanislav {\vS}p{\'a}nik and Moshe Josef Inbar and Christoph Carl Zielinski},
  journal={Breast Cancer Research and Treatment},
  year={2009},
  volume={119},
  pages={169-176}
}
Docetaxel (D) plus gemcitabine (G) is an active combination in anthracycline pre-treated breast cancer. Impact of sequential administration of these drugs is unclear. This trial aimed to compare concomitant DG with sequential D → G. Patients were randomised to eight cycles of gemcitabine 1,000 mg/m2 on days 1 + 8 plus docetaxel 75 mg/m2 on day 8, or 4… CONTINUE READING